Eli Lilly (LLY) Net Margin (2009 - 2026)

Eli Lilly (LLY) has reported Net Margin for 17 consecutive years, with 37.36% the latest figure, recorded in Q1 2026.

• Net Margin for Q1 2026 came in at 37.36%, up 1568.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 34.99% (up 1232.0% YoY), and the FY2025 annual result was 31.67%, up 816.0% from the prior year.
• Net Margin was 37.36% for Q1 2026 at Eli Lilly, up from 34.41% in the prior quarter.
• Over five years, Net Margin peaked at 37.36% in Q1 2026 and troughed at 0.6% in Q3 2023.
• Average Net Margin over 5 years is 23.78%, with a median of 24.36% recorded in 2022.
• Year-over-year, Net Margin slumped 2152 bps in 2023 and jumped 2323 bps in 2025.
• Over 5 years, Net Margin stood at 26.54% in 2022, then dropped by 12 bps to 23.41% in 2023, then jumped by 39 bps to 32.59% in 2024, then gained by 6 bps to 34.41% in 2025, then grew by 9 bps to 37.36% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 37.36% in Q1 2026, 34.41% in Q4 2025, and 31.72% in Q3 2025.